Modeling prognostic factors in resectable pancreatic adenocarcinomas
- PMID: 20508721
- PMCID: PMC2865167
- DOI: 10.4137/cin.s3835
Modeling prognostic factors in resectable pancreatic adenocarcinomas
Abstract
Background: The accurate prognosis for patients with resectable pancreatic adenocarcinomas requires the incorporation of more factors than those included in AJCC TNM system.
Methods: We identified 218 patients diagnosed with stage I and II pancreatic adenocarcinoma at NewYork-Presbyterian Hospital/Columbia University Medical Center (1999 to 2009). Tumor and clinical characteristics were retrieved and associations with survival were assessed by univariate Cox analysis. A multivariable model was constructed and a prognostic score was calculated; the prognostic strength of our model was assessed with the concordance index.
Results: Our cohort had a median age of 67 years and consisted of 49% men; the median follow-up time was 14.3 months and the 5-year survival 3.6%. Age, tumor differentiation and size, alkaline phosphatase, albumin and CA 19-9 were the independent factors of the final multivariable model; patients were thus classified into low (n = 14, median survival = 53.7 months), intermediate (n = 124, median survival = 19.7 months) and high risk groups (n = 80, median survival = 12.3 months). The prognostic classification of our model remained significant after adjusting for adjuvant chemotherapy and the concordance index was 0.73 compared to 0.59 of the TNM system.
Conclusion: Our prognostic model was accurate in stratifying patients by risk and could be incorporated into clinical decisions.
Keywords: multivariable model; pancreatic adenocarcinomas; prognosis; survival.
Figures

Similar articles
-
Developing a multivariable prognostic model for pancreatic endocrine tumors using the clinical data warehouse resources of a single institution.Appl Clin Inform. 2010;1(1):38-49. doi: 10.4338/ACI-2009-12-RA-0026. Appl Clin Inform. 2010. PMID: 21552466 Free PMC article.
-
Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis.BMC Cancer. 2020 Jun 9;20(1):541. doi: 10.1186/s12885-020-07023-9. BMC Cancer. 2020. PMID: 32517802 Free PMC article.
-
[Preoperative C-reactive protein/albumin ratio predicts the prognosis of patients with resectable pancreatic cancer].Zhonghua Wai Ke Za Zhi. 2018 Sep 1;56(9):712-717. doi: 10.3760/cma.j.issn.0529-5815.2018.09.013. Zhonghua Wai Ke Za Zhi. 2018. PMID: 30157579 Chinese.
-
Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.Lancet Oncol. 2018 May;19(5):629-638. doi: 10.1016/S1470-2045(18)30108-6. Epub 2018 Mar 19. Lancet Oncol. 2018. PMID: 29567071
-
[Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jan 25;22(1):73-78. Zhonghua Wei Chang Wai Ke Za Zhi. 2019. PMID: 30703797 Chinese.
Cited by
-
A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer.BMJ Open. 2019 Aug 21;9(8):e027192. doi: 10.1136/bmjopen-2018-027192. BMJ Open. 2019. PMID: 31439598 Free PMC article.
-
The Nomogram predicting the overall survival of patients with pancreatic cancer treated with radiotherapy: a study based on the SEER database and a Chinese cohort.Front Endocrinol (Lausanne). 2023 Oct 25;14:1266318. doi: 10.3389/fendo.2023.1266318. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37955009 Free PMC article.
-
Combining PubMed knowledge and EHR data to develop a weighted bayesian network for pancreatic cancer prediction.J Biomed Inform. 2011 Oct;44(5):859-68. doi: 10.1016/j.jbi.2011.05.004. Epub 2011 May 27. J Biomed Inform. 2011. PMID: 21642013 Free PMC article.
-
Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma.Medicine (Baltimore). 2016 Jul;95(27):e4065. doi: 10.1097/MD.0000000000004065. Medicine (Baltimore). 2016. PMID: 27399091 Free PMC article.
-
A population-based study of synchronous distant metastases and prognosis in patients with PDAC at initial diagnosis.Front Oncol. 2023 Jan 26;13:1087700. doi: 10.3389/fonc.2023.1087700. eCollection 2023. Front Oncol. 2023. PMID: 36776324 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49. - PubMed
-
- Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79. - PubMed
-
- Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247:456–62. - PubMed
-
- Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008;112:243–9. - PubMed
-
- Labianca R, Berardi E, Malugani F. Challenges in the treatment of gastrointestinal tumours. Ann Oncol. 2006;17(Suppl 5):v137–41. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources